ARE YOUR PATIENTS ON THE OPTIMAL DIABETES THERAPY?

POOR GLYCAEMIC CONTROL\* IS PREVALENT IN APPROXIMATELY

65-70% of Adults with Type 1 Diabetes\(^1\)

52% of People with Type 2 diabetes, requiring insulin\(^2\)

42% of People with Type 2 diabetes, requiring oral medications\(^2\)

USING REAL-TIME CGM FOR DIAGNOSTIC PURPOSES MAY NOT REFLECT THE PATIENTS’ TRUE GLYCAEMIC PROFILE

Patients change their behavior when they see their Real-Time CGM glucose values\(^3\)

Improvement in glucose control is not sustained when Real-Time CGM is removed\(^4\)

DATA FROM THE GOLD RANDOMIZED CLINICAL TRIAL AIMED TO EVALUATE THE EFFECTS OF CONTINUOUS GLUCOSE MONITORING IN 161 ADULTS WITH TYPE 1 DIABETES TREATED WITH MULTIPLE DAILY INSULIN INJECTIONS.

POOR GLYCAEMIC CONTROL IS PREVALENT IN APPROXIMATELY

BASELINE HBA1C
REAL-TIME CGM INITIATED

PATIENT RETURNS TO NEAR BASELINE HBA1C

REAL-TIME CGM REMOVED

Data from the GOLD Randomized Clinical trial aimed to evaluate the effects of continuous glucose monitoring in 161 adults with type 1 diabetes treated with multiple daily insulin injections.

BLINDED CGM FACILITATES CHANGES IN TREATMENT DECISIONS WHICH LEADS TO IMPROVEMENT IN HBA1C AND TIME IN RANGE\(^5\)**

\(1.3\% \downarrow\) HbA1c 7% \(\uparrow\) Time in Range

\(p<0.0001\)  \(p<0.01\)

In a prospective, one year study with 90 patients with insulin requiring Type 2 diabetes, improvement in clinical outcomes was achieved by optimizing treatment after review of blinded CGM reports. HbA1c was reduced at 4 months \(p<0.0001\) and sustained for 1 year \(p<0.0001\).

CGM BLINDED TO THE PATIENT PROVIDES A BASELINE GLYCAEMIC PROFILE TO DETERMINE THE OPTIMAL THERAPY\(^6\)**

\* HbA1C >8.0%.

\**Study was conducted using iPro™ 2 Professional CGM.


MEET ENVISION™ PRO: YOUR KEY TO UNLOCK THE RIGHT THERAPY

OPTIMAL DATA
- Blinded to the Patient
- Comprehensive Event Tracking
- Easy to read reports

SUPERIOR DESIGN
- Zero Calibrations
- Fully Disposable
- Automatic Data Upload

ENVISION™ PRO COULD BE USED FOR INDIVIDUALS WITH DIABETES** THAT ARE NOT USING PERSONAL CGM AND BASED ON THE BELOW USE CASES

HCP OBJECTIVE
- Therapy optimization¹
- Intensify
- De-intensify
- Fine-tuning
- New Patient Evaluation
- Educational Tool
- Before / after bariatric surgery
- Clinical trials

PATIENT PROFILE
- Individuals with type 1 or type 2 diabetes** with any of the following attributes
  - Less tech-savvy
  - Non-intensive therapy
  - Overwhelmed by data, alarms
  - Want minimal intervention during the evaluation
  - Cannot afford Personal CGM

FOR MORE INFORMATION VISIT: hcp.medtronic-diabetes.co.uk

*Sensor is applied with One-Press Serter.
**Indicated for individuals with type 1 or type 2 diabetes ages 14 and above.

Important Safety Information
The Envision™ Pro CGM system is intended to record interstitial glucose levels in persons with diabetes mellitus. The data collected by the Envision™ recorder is uploaded to a computer and the reports are reviewed by healthcare professionals. The reports may allow identification of patterns of glucose excursions above and below a desired range, facilitating therapy adjustments, which may minimize these excursions. This information is a real-time supplement, not replace. Actual glucose information obtained using standard home glucose monitoring devices. For more details, please see https://hcp.medtronic-diabetes.co.uk/